HealthDay Information — For community-dwelling older adults with out medical heart problems, atorvastatin is related to a decrease threat for main cardiovascular occasions, however doesn’t enhance disability-free survival, in response to a examine printed on-line Aug. 28 within the New England Journal of Drugs to coincide with the annual assembly of the European Society of Cardiology, held from Aug. 28 to 31 in Munich.
Sophia Zoungas, M.B., B.S., Ph.D., from Monash College in Melbourne, Australia, and colleagues carried out a double-blind, placebo-controlled trial at basic medical practices throughout Australia to look at the effectiveness and security of statins for the first prevention of cardiovascular occasions and the extension of disability-free survival amongst older adults. Group-dwelling adults aged 70 years and older with no historical past of cardiovascular disease, diabetes, or dementia had been randomly assigned to obtain atorvastatin 40 mg as soon as day by day or similar placebo (4,984 and 4,987 individuals, respectively).
The researchers discovered that after a median of 5.9 years, a major cardiovascular occasion occurred in 297 and 412 individuals within the atorvastatin and placebo teams, respectively (10.9 and 15.5 occasions per 1,000 person-years, respectively; hazard ratio, 0.70; 95 p.c confidence interval, 0.61 to 0.82; P < 0.001). Dying from any trigger, dementia, or persistent bodily incapacity occurred in 637 and 676 individuals within the atorvastatin and placebo teams, respectively (21.6 and 23.0 occasions per 1,000 person-years, respectively; hazard ratio, 0.94; 95 p.c confidence interval, 0.84 to 1.05; P = 0.25). Critical adversarial occasions occurred in 2.7 p.c of individuals in every group, with musculoskeletal, hepatobiliary, and diabetes-related adversarial occasions occurring extra ceaselessly within the atorvastatin group.
“The danger of coronary heart assault and stroke is a priority for older individuals and realizing there may be an efficient measure for reducing that threat shall be an enormous reassurance to older individuals and their households,” Zoungas mentioned in a press release.
A number of authors disclosed ties to the biopharmaceutical business.
Abstract/Full Text (subscription or payment may be required)
